Feasibility, long-term safety, and immune monitoring of regulatory T cell therapy in living donor kidney transplant recipients
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Short-term outcomes in kidney transplantation are marred by progressive transplant failure and mortality secondary to immunosuppression toxicity. Immune modulation with autologous polyclonal regulatory T cell (Treg) therapy may facilitate immunosuppression reduction promoting better long-term clinical outcomes. In a Phase I clinical trial, 12 kidney transplant recipients received 1–10 × 106 Treg per kg at Day +5 posttransplantation in lieu of induction immunosuppression (Treg Therapy cohort). Nineteen patients received standard immunosuppression (Reference cohort). Primary outcomes were rejection-free and patient survival. Patient and transplant survival was 100%; acute rejection-free survival was 100% in the Treg Therapy versus 78.9% in the reference cohort at 48 months posttransplant. Treg therapy revealed no excess safety concerns. Four patients in the Treg Therapy cohort had mycophenolate mofetil withdrawn successfully and remain on tacrolimus monotherapy. Treg infusion resulted in a long-lasting dose-dependent increase in peripheral blood Tregs together with an increase in marginal zone B cell numbers. We identified a pretransplantation immune phenotype suggesting a high risk of unsuccessful ex-vivo Treg expansion. Autologous Treg therapy is feasible, safe, and is potentially associated with a lower rejection rate than standard immunosuppression. Treg therapy may provide an exciting opportunity to minimize immunosuppression therapy and improve long-term outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Human FOXP3+ Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer
Wing, J. B., Tanaka, A., & Sakaguchi, S. (2019) · Immunity · doi:10.1016/j.immuni.2019.01.020 · Cited by 726
Single-Cell Transcriptomics of Regulatory T Cells Reveals Trajectories of Tissue Adaptation
Miragaia, R. J., Gomes, T., Chomka, A., Jardine, L., Riedel, A., Hegazy, A. N., Whibley, N., Tucci, A., Chen, X., Lindeman, I., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.01.001 · Cited by 499
Cited by
Treg cell therapy: How cell heterogeneity can make the difference
Giganti, G., Atif, M., Mohseni, Y., Mastronicola, D., Grageda, N., Povoleri, G. A., Miyara, M., & Scottà, C. (2021) · European Journal of Immunology · doi:10.1002/eji.201948131 · Cited by 82
Self-citationUpdate on islet cell transplantation
Verhoeff, K., Marfil-Garza, B. A., & Shapiro, A. M. J. (2021) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000891 · Cited by 29
Metadata
- Authors
- Harden, P. N., Game, D. S., Sawitzki, B., Van der Net, J. B., Hester, J., Bushell, A., Issa, F., Brook, M. O., Alzhrani, A., Schlickeiser, S., Scotta, C., Petchey, W., Streitz, M., Blancho, G., Tang, Q., Markmann, J., Lechler, R. I., Roberts, I. S. D., Friend, P. J., Hilton, R., Geissler, E. K., Wood, K. J., & Lombardi, G.
- Venue
- American Journal of Transplantation
- Publisher
- Elsevier BV
- Published
- 2021-04
- Volume
- 21
- Issue
- 4
- Pages
- 1603-1611
- ISSN
- 1600-6135 (ISSN-L)
- OpenAlex
- W3100659075
- Cited by
- 126
- References
- 2
- FWCI
- 15.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Feasibility, long-term safety, and immune monitoring of regulatory T cell therapy in living donor kidney transplant recipients. https://app.cochat.ai/papers/10.1111/ajt.16395
- The paper
- Harden, P. N., Game, D. S., Sawitzki, B., Van der Net, J. B., Hester, J., Bushell, A., Issa, F., Brook, M. O., Alzhrani, A., Schlickeiser, S., Scotta, C., Petchey, W., Streitz, M., Blancho, G., Tang, Q., Markmann, J., Lechler, R. I., Roberts, I. S. D., Friend, P. J., . . . Lombardi, G. (2021). Feasibility, long-term safety, and immune monitoring of regulatory T cell therapy in living donor kidney transplant recipients. American Journal of Transplantation. https://doi.org/10.1111/ajt.16395
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.